Table 3.

Distribution and RRs with 95% CIs for prostate cancer risk according to quintiles of HCAs and BaP

VariableQuintilePtrend*
1 (reference)2345
DiMeiQx
    Range (ng/d)0.0-0.2>0.2-0.7>0.7-1.6>1.6-3.4>3.4-159.0
    Total cases (n)277310276242233
    RR (95% CI)1.01.14 (0.96-1.35)1.04 (0.86-1.25)0.94 (0.76-1.16)0.98 (0.77-1.25)0.40
    RR (95% CI)1.01.09 (0.89-1.34)1.11 (0.89-1.41)0.93 (0.71-1.22)0.98 (0.71-1.33)0.37
    RR (95% CI)§1.00.93 (0.71-1.23)1.00 (0.74-1.36)1.04 (0.74-1.46)1.03 (0.69-1.53)0.75
MeIQx
    Range (ng/d)0.0-9.8>9.8-19.4>19.4-33.1>33.1-59.4>59.4-1230.8
    Total cases (n)299300260242237
    RR (95% CI)1.01.04 (0.88-1.24)1.00 (0.82-1.22)0.97 (0.78-1.21)0.97 (0.76-1.24)0.67
    RR (95% CI)1.01.03 (0.83-1.26)0.84 (0.66-1.08)0.87 (0.67-1.15)0.90 (0.66-1.22)0.49
    RR (95% CI)§1.01.08 (0.82-1.43)0.94 (0.68-1.31)0.99 (0.70-1.42)0.95 (0.64-1.43)0.61
PhIP
    Range (ng/d)0.0-25.5>25.5-56.1>56.1-112.7>112.7-269.2>269.2-7862.9
    Total cases (n)280280272247259
    RR (95% CI)1.01.05 (0.88-1.24)1.07 (0.89-1.27)1.04 (0.87-1.25)1.22 (1.01-1.48)0.04
    RR (95% CI)1.00.98 (0.80-1.22)1.07 (0.86-1.33)1.00 (0.79-1.26)1.28 (1.01-1.61)0.01
    RR (95% CI)§1.01.00 (0.76-1.30)1.01 (0.76-1.33)0.88 (0.65-1.18)1.06 (0.78-1.43)0.59
BaP
    Range (ng/d)0.0-1.2>1.2-4.2>4.2-18.0>18.0-64.6>64.6-1031.5
    Total cases (n)305282287244220
    RR (95% CI)1.01.00 (0.85-1.18)1.01 (0.86-1.19)0.93 (0.78-1.10)0.94 (0.79-1.13)0.36
    RR (95% CI)1.00.96 (0.78-1.18)1.07 (0.87-1.30)0.94 (0.76-1.16)0.95 (0.76-1.18)0.54
    RR (95% CI)§1.000.85 (0.65-1.11)0.95 (0.74-1.23)0.94 (0.72-1.22)0.85 (0.64-1.13)0.49
Mutagenic activity (per 1,000 revertant colonies/d)
    Range (μg/d)0.0-1.7>1.7-3.4>3.4-5.9>5.9-11.4>11.4-503.0
    Total cases (n)301294264240239
    RR (95% CI)1.01.02 (0.87-1.21)1.01 (0.85-1.19)0.98 (0.82-1.16)1.04 (0.87-1.24)0.73
    RR (95% CI)1.00.98 (0.81-1.19)0.87 (0.71-1.07)0.86 (0.69-1.07)1.03 (0.83-1.28)0.56
    RR (95% CI)§1.00.85 (0.65-1.11)0.96 (0.74-1.26)1.03 (0.79-1.36)0.94 (0.71-1.26)0.97
  • NOTE: Multivariate models included age, race, study center, family history of prostate cancer, history diabetes, number of screening exams during follow-up, smoking status, physical activity, aspirin use, body mass index, and intake of total energy, supplemental vitamin E, and lycopene.

  • * Ptrend across quintiles using the median value of each quintile.

  • All cases (n = 1,338).

  • Incident cases (n = 868).

  • § Advanced cases (n = 520).